Onkure Therapeutics, INC

OnKure Therapeutics reported first quarter 2026 financial results, highlighting the nomination of two new drug candidates, OKI-355 and OKI-345, and a $150 million private placement to fund clinical development.

OnKure Therapeutics secured ~$150 million via a private placement of common stock and pre-funded warrants, granted board nomination rights to the lead investor, and outlined pipeline milestones, including INDs for next‑gen PI3K pan‑mutant programs in H1 2027.

OnKure Therapeutics, Inc. has entered into a sales agreement with Leerink Partners LLC to establish an 'at-the-market' equity offering program for its Class A common stock.

OnKure Therapeutics reported its third quarter 2025 financial results, revealing increased net losses and a delay in the release of initial clinical data for its lead oncology program, OKI-219, until Q1 2026.

OnKure Therapeutics reported second quarter 2025 financial results and provided a business update, highlighting progress in its PIKture-01 clinical trial and a cash runway into Q4 2026.

OnKure Therapeutics, Inc. has released an updated corporate presentation showcasing positive early Phase 1 clinical trial results for its highly selective PI3K inhibitor, OKI-219, and confirming a cash runway extending into the fourth quarter of 2026.

OnKure Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting a significant increase in cash and cash equivalents following a private placement, while continuing to advance its pipeline of precision medicines.

OnKure Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and a significant decrease in cash and cash equivalents for the third quarter of 2025, highlighting ongoing funding needs for its cancer drug development.

OnKure Therapeutics reported a widened net loss in Q2 2025, driven by increased research and development expenses for its lead cancer drug candidate, OKI-219, while maintaining sufficient cash runway for the next 12 months.

OnKure Therapeutics reports its first financial results post-merger, highlighting ongoing clinical trials and a focus on precision medicines for cancer.

OnKure Therapeutics, formerly Reneo Pharmaceuticals, completed its merger and reported its financial results for the quarter ended September 30, 2024.

Reneo Pharmaceuticals has entered into a merger agreement with OnKure, Inc., while also suspending development of its lead drug candidate, mavodelpar, following disappointing trial results.

OnKure Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and a going concern warning, despite advancing its lead cancer drug candidate, OKI-219, through Phase 1 trials with favorable preliminary safety data.

OnKure Therapeutics reports its 2024 financial results and provides an update on its clinical development programs, including OKI-219.

Reneo Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and corporate governance.

Reneo Pharmaceuticals suspends development of mavodelpar after a failed clinical trial and initiates a strategic review process to maximize stockholder value.

Nicholas Saccomano, President and CEO of OnKure Therapeutics, Inc., reported a transaction involving the sale of Class A Common Stock to cover tax withholding obligations upon the vesting of Restricted Stock Units.

OnKure Therapeutics, Inc. reports that Chief Financial Officer Jason A. Leverone sold shares to cover tax obligations related to RSU vesting.

Director Edward T. Mathers was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard equity compensation.

Director Liam Ratcliffe was granted 1,275 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Director Andrew John Phillips was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Director Valerie Malyvanh Jansen was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

OnKure Therapeutics, Inc. has filed its proxy statement for the 2026 annual meeting of stockholders to be held on June 3, 2026.

Onkure Therapeutics, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

OnKure Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on May 27, 2025, to elect directors and ratify the appointment of its independent auditor.

OnKure Therapeutics registers the resale of 2.9 million shares of Class A Common Stock issued in a private placement following its merger with Reneo Pharmaceuticals.

AI Biotechnology LLC, along with affiliated entities and Len Blavatnik, has reported beneficial ownership of 19.99% of OnKure Therapeutics' Class A Common Stock following a private placement and warrant acquisition.

Acorn Bioventures and its affiliates have significantly increased their beneficial ownership in OnKure Therapeutics, Inc. to 22.1% through recent share acquisitions and a prior merger.

Investment firms Acorn Bioventures and its affiliates, along with manager Anders Hove, have disclosed a substantial beneficial ownership stake in OnKure Therapeutics, Inc., primarily for investment purposes.

A group of investment entities and individuals associated with RiverVest Venture Funds has reported ceasing beneficial ownership of more than 5% of OnKure Therapeutics, Inc.'s common stock.

Several Biotechnology Value Funds and Mark N. Lampert have updated their beneficial ownership of OnKure Therapeutics' Class A Common Stock, reporting holdings as of May 27, 2026.

ADAR1 Capital Management and Daniel Schneeberger have reported a 6% beneficial ownership stake in OnKure Therapeutics, Inc. as of March 31, 2026.

StepStone Group and its affiliates have disclosed beneficial ownership of 2,660,612 shares, representing 6.6% of OnKure Therapeutics' Class A Common Stock.

Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have reported beneficial ownership of 6.0% of OnKure Therapeutics, Inc.'s Class A Common Stock as of March 31, 2026.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a Schedule 13G, jointly reporting beneficial ownership of 9.9% of OnKure Therapeutics, Inc. Class A common stock.

Acorn Bioventures and related entities disclose a significant beneficial ownership stake in OnKure Therapeutics, Inc., reaching up to 9.5%.